Lupin, Mark Cuban’s Cost Plus Drugs and COPD Foundation boost COPD treatment access
In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost ... Read More
Lupin clinches FDA approval for generic Spiriva HandiHaler
Indian pharma titan Lupin has announced receiving approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Tiotropium Bromide ... Read More
Lupin gets Health Canada approval for generic Spiriva for COPD treatment
Lupin has announced that its subsidiary in Canada, Lupin Pharma Canada has received approval from Health Canada to market a generic version of Spiriva (tiotropium ... Read More
Lupin bags UK approval for Lutio inhalation product for COPD treatment
Lupin through its subsidiary — Lupin Healthcare (UK) has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lutio, a generic ... Read More
Glenmark Pharmaceutical launches Tiogiva in UK for COPD treatment
Glenmark Pharmaceutical has announced the UK launch of Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI), for the treatment of chronic obstructive ... Read More